Metazine MR® is a preparation of Trimetazidine Hydrochloride. Trimetazidine Hydrochloride is a unique antianginal and anti-ischemic agent that exerts anti-ischemic effects without inducing hemodynamic changes and improves the status of ischemic myocardium. The drug exerts its antianginal effects through a direct cytoprotective action on the myocardium, thereby avoiding the side effects of impaired left ventricular function, excessive vasodilation and other disadvantages associated with the use of comparator antianginal agents. Trimetazidine Hydrochloride is indicated for Ischemic heart disease (angina pectoris, sequelae of infarction) Adjuvant symptomatic treatment of vertigo and tinnitus. Adjuvant treatment of the decline visual acuity and visual field disturbances, presumably of vascular origin.